ModerateVitamin K antagonist anticoagulants×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Phenytoin is a strong inducer of liver enzymes that metabolise drugs. The Spanish phenytoin SmPCs list oral anticoagulants among the drugs whose levels or effect it can alter or reduce, although acenocoumarol is not among the examples (phenytoin SmPCs, AEMPS; phenytoin prescribing information, US Food and Drug Administration, FDA). According to the acenocoumarol SmPC, serum phenytoin levels can rise during concomitant treatment. The SmPC does not give the mechanism (acenocoumarol SmPC, AEMPS). CYP2C9 is the main enzyme that metabolises phenytoin. This metabolism is saturable, and its inhibition can raise phenytoin levels considerably (phenytoin SmPC, AEMPS). The documents contain no study with acenocoumarol. For warfarin, the US phenytoin label reports both increased and decreased international normalised ratio (INR) responses. It also lists warfarin among the drugs that raise phenytoin levels (phenytoin prescribing information, FDA).
Symptoms
The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol and phenytoin summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). For warfarin, the US phenytoin label reports INR shifts in both directions (phenytoin prescribing information, US Food and Drug Administration, FDA). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). When phenytoin levels rise, the first signs are nystagmus, loss of coordination (ataxia) and slurred speech. Tremor, drowsiness, blurred vision, nausea and vomiting follow (phenytoin SmPC, overdose section, AEMPS). Phenytoin levels above the optimal range can cause confusion (phenytoin SmPC, AEMPS).
Management
The combination is not contraindicated but needs close monitoring of coagulation and of phenytoin levels. The acenocoumarol summary of product characteristics (SmPC) asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added to acenocoumarol and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Measure serum phenytoin levels when an interaction is suspected (phenytoin SmPCs, AEMPS; phenytoin prescribing information, US Food and Drug Administration, FDA). When needed, check them 7–10 days after another drug is added or stopped, once the new steady state is reached. Most patients have optimal seizure control without signs of toxicity at 10–20 micrograms/ml (phenytoin SmPC, AEMPS). At the first sign of phenytoin toxicity, measure its level and reduce the dose if the level is high (phenytoin SmPC, AEMPS). For warfarin, the US phenytoin label states that adding or stopping phenytoin may require a change in the warfarin dose (phenytoin prescribing information, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Dilantin (extended phenytoin sodium capsules) – prescribing information (2023)– FDA label, Viatris Specialty, DailyMed setid 86dd27d1-9cee-48ae-b55d-e2d2f7dbc593, version 3, 08/2023, section 7.2 (Drugs Affected by Phenytoin)
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2
- AEMPS: Ficha técnica: Fenitoína, Epanutin 100 mg (nº registro 45695), sección 4.4 (2024)– AEMPS, CIMA, nº registro 45695 (Epanutin 100 mg cápsulas duras, Viatris), revisión 01/2024 (texto revisado 09/2021), secciones 4.2, 4.4, 4.9 y 5.2
- AEMPS: Ficha técnica: Fenitoína Altan 50 mg/ml solución inyectable (nº registro 65372), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65372 (Fenitoína Altan 50 mg/ml solución inyectable, Altan Pharmaceuticals), revisión 08/2026 (texto revisado 09/2025), sección 4.5